RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis
Abstract Background Triple negative breast cancer (TNBC) is one of the most lethal breast cancer subtypes. Due to a lack of effective therapeutic targets, chemotherapy is still the main medical treatment for TNBC patients. Thus, it is important and necessary to find new therapeutic targets for TNBC....
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | Cell Communication and Signaling |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12964-022-00963-8 |